Almac to Create 348 New Jobs and Invest GBP 54 Million in Pharma and Clinical Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Almac to Create 348 New Jobs and Invest GBP 54 Million in Pharma and Clinical Services


Enterprise, Trade and Investment Minister Arlene Foster has announced that the Almac Group is investing more than £54 million and creating 348 high quality jobs over the next five years.

The Almac Group operates in the pharmaceutical and biotechnology sectors providing services including drug discovery, diagnostics, R&D, manufacture of APIs, formulation development, and clinical trials.

The company employs more than 2,100 staff at its headquarters in Craigavon, with an additional 1,380 staff located in facilities across the United Kingdom, United States, and Asia. The investment, supported by Invest Northern Ireland, relates to two of Almac’s operating business units, Pharma Services and Clinical Services.

Arlene Foster commented during the announcement that Almac’s investment will enable the organization to expand the range of services it offers and enhance its market position as it responds to key trends within the pharmaceutical industry.

Almac Pharma Services provides contract development and manufacturing services to the world’s leading pharmaceutical and biotech companies. According to the press release, besides recruiting 141 new staff over the next five years, the company will invest in new technologies and equipment to take advantage of the growing demand for outsourced development services.

Almac Clinical Services provides clinical packaging, labelling, logistics, and clinical supply-chain management services to the pharmaceutical industry. It is investing in cold-chain storage and distribution facilities and enhanced information systems to capitalize on the demand from clients for closer partnering opportunities. The unit is creating 181 new jobs over the next five years.

The investments will also create a further 26 new jobs within the Group.
“These 348 new jobs will generate salaries of over £9.4m per annum when the projects are fully implemented. This is a significant cash injection for the local economy. The investments are also good news for our growing life sciences sector, which is gaining an international reputation for innovation and excellence,” Foster added.

Invest Northern Ireland has offered Almac Group £5.5m of support towards its investment. Alan Armstrong, chairman and CEO of the Almac Group, said in a press statement, “We are fortunate to employ an excellent highly-skilled workforce at our Craigavon headquarters, which has played a major role in our global growth. It’s fantastic that demand for our services has resulted in the creation of so many new jobs as we embark on further expansion over the next five years.”

Source: Almac

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here